Anti-Nivolumab (Opdivo®)
- SKU:
- TM09030
- Bulk Pricing:
-
- Buy 5 - 20 and get 5% off
- Buy 21 - 30 and get 10% off
- Buy 31 - 50 and get 15% off
- Buy 51 or more – call for best pricing
The cookie settings on this website are set to 'allow all cookies' to give you the very best experience. Please click Accept Cookies to continue to use the site.
ImmunoGuide® Enzyme immunoassay (ELISA) for the determination of free antibodies to Nivolumab in serum and plasma.<br><br>
The drug Nivolumab (Opdivo®) is a fully human IgG4 monoclonal antibody that binds specifically to programmed death-1 (PD-1), a negative regulatory receptor expressed by activated T and B lymphocytes. Binding of Nivolumab to the PD-1 receptor blocks its interaction with the ligands, PDL1 and PD-L2, thereby attenuating PD-1–mediated inhibition of the immune response, including the anti-tumor immune response. One of the major concerns, despite of its wide usage, is the potential development of anti-drug antibodies (ADA) which in turn may interfere with the drug efficacy as mainly judged by observing the relapse of signs and symptoms of disease and necessitate dose-escalation or potentially ending up the treatment.<br><br>
The ImmunoGuide Antibody to Nivolumab ELISA Kit can be used for the measurement of free antibodies against this drug. It does not detect such antibodies which already are bound to the drug. For research purposes only, not for use in diagnostic procedures.
ImmunoGuide® Enzyme immunoassay (ELISA) for the determination of free antibodies to Nivolumab in serum and plasma.<br><br>
The drug Nivolumab (Opdivo®) is a fully human IgG4 monoclonal antibody that binds specifically to programmed death-1 (PD-1), a negative regulatory receptor expressed by activated T and B lymphocytes. Binding of Nivolumab to the PD-1 receptor blocks its interaction with the ligands, PDL1 and PD-L2, thereby attenuating PD-1–mediated inhibition of the immune response, including the anti-tumor immune response. One of the major concerns, despite of its wide usage, is the potential development of anti-drug antibodies (ADA) which in turn may interfere with the drug efficacy as mainly judged by observing the relapse of signs and symptoms of disease and necessitate dose-escalation or potentially ending up the treatment.<br><br>
The ImmunoGuide Antibody to Nivolumab ELISA Kit can be used for the measurement of free antibodies against this drug. It does not detect such antibodies which already are bound to the drug. For research purposes only, not for use in diagnostic procedures.